Professor Nigel Temperton

Chair in Molecular Virology



01634 202957


Medway School of Pharmacy

University of Kent

Medway School of Pharmacy,
Anson Building,
Central Avenue,
Chatham Maritime,
Kent, ME4 4TB
United Kingdom



Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds


Journal article


D. Cantoni, M. Mayora-Neto, A. Nadesalingam, D. Wells, G. Carnell, Luis Ohlendorf, Matteo Ferrari, P. Palmer, A. Chan, Peter Smith, E. Bentley, Sebastian Einhauser, R. Wagner, M. Page, G. Raddi, H. Baxendale, J. Castillo-Olivares, J. Heeney, Nigel J. Temperton
Frontiers in Immunology, 2022

Semantic Scholar DOI PubMedCentral PubMed
Cite

Cite

APA   Click to copy
Cantoni, D., Mayora-Neto, M., Nadesalingam, A., Wells, D., Carnell, G., Ohlendorf, L., … Temperton, N. J. (2022). Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds. Frontiers in Immunology.


Chicago/Turabian   Click to copy
Cantoni, D., M. Mayora-Neto, A. Nadesalingam, D. Wells, G. Carnell, Luis Ohlendorf, Matteo Ferrari, et al. “Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds.” Frontiers in Immunology (2022).


MLA   Click to copy
Cantoni, D., et al. “Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds.” Frontiers in Immunology, 2022.


BibTeX   Click to copy

@article{d2022a,
  title = {Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds},
  year = {2022},
  journal = {Frontiers in Immunology},
  author = {Cantoni, D. and Mayora-Neto, M. and Nadesalingam, A. and Wells, D. and Carnell, G. and Ohlendorf, Luis and Ferrari, Matteo and Palmer, P. and Chan, A. and Smith, Peter and Bentley, E. and Einhauser, Sebastian and Wagner, R. and Page, M. and Raddi, G. and Baxendale, H. and Castillo-Olivares, J. and Heeney, J. and Temperton, Nigel J.}
}

Abstract

The rise of SARS-CoV-2 variants has made the pursuit to define correlates of protection more troublesome, despite the availability of the World Health Organisation (WHO) International Standard for anti-SARS-CoV-2 Immunoglobulin sera, a key reagent used to standardise laboratory findings into an international unitage. Using pseudotyped virus, we examine the capacity of convalescent sera, from a well-defined cohort of healthcare workers (HCW) and Patients infected during the first wave from a national critical care centre in the UK to neutralise B.1.1.298, variants of interest (VOI) B.1.617.1 (Kappa), and four VOCs, B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta), including the B.1.617.2 K417N, informally known as Delta Plus. We utilised the WHO International Standard for anti-SARS-CoV-2 Immunoglobulin to report neutralisation antibody levels in International Units per mL. Our data demonstrate a significant reduction in the ability of first wave convalescent sera to neutralise the VOCs. Patients and HCWs with more severe COVID-19 were found to have higher antibody titres and to neutralise the VOCs more effectively than individuals with milder symptoms. Using an estimated threshold for 50% protection, 54 IU/mL, we found most asymptomatic and mild cases did not produce titres above this threshold.





Follow this website


You need to create an Owlstown account to follow this website.


Sign up

Already an Owlstown member?

Log in